FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are
O
ncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC),
Exelixis, Inc. (NASDAQ:EXEL),
Mirati Therapeutics, Inc. (NASDAQ:MRTX),
Eli Lilly and Company (NYSE:LLY), and
POINT Biopharma Global Inc. (NASDAQ:PNT).
One of the latest developments from
O
ncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is an update on its flagship asset, pelareorep, and its ongoing GOBLET Phase 1/2 study. Within its pancreatic cancer segment, the study has delivered plenty of optimistic results, with the latest update coming at the European Society for Medical Oncology (ESMO) Congress 2023, at the IFEMA Madrid Conference Center in Madrid, Spain.
Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the
FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer. By mid-2023, the
Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial, called Precision Promise.
Upon the announcement that pelareorep had been chosen, the market swiftly reacted, boosting
ONCY's stock. The company successfully secured an additional US$15 million, to advance their trials for both pancreatic and metastatic breast cancers. This funding round even included substantial backing from an institutional investor. As per their most recent Q2 2023 financial report,
Oncolytics had a pro forma balance of CAD$42.7 million as of June 30, 2023. This is projected to sustain the company's operations until H2 2024.
Within the GOBLET study's latest data on pelareorep in combination with the PD-L1 inhibitor atezolizumab (atezo) and chemotherapy is new data, including a 6-month progression-free survival (PFS) rate was 72.9%, and a 6-month overall survival (OS) rate of 82.1%—both significantly high for the industry standard.
A 72.9% PFS at 6 months is a positive signal, as many other therapies struggle to reach such a high percentage of patients experiencing no progression at that point. The same goes for a 6-month OS of 82.1%, as it indicates that a significant majority of patients are surviving to this point, which is better than what is commonly seen. For reference, considering all stages of pancreatic cancer, only around 25 in every 100 (25%) survive their diagnosis for 1 year or more.
As well, the pelareorep combination therapy's overall response rate (ORR) was 62%. For reference,
Oncolytics' 62% ORR is more than double the historical control trial titled Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine which yielded only a ~25% ORR.
Back in August,
Exelixis, Inc. (NASDAQ:EXEL) announced it had ended its Cabometyx study early, after researchers saw "dramatic improvement" in neuroendocrine tumors treated with cabozantinib (CABOMETYX)—namely patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors who progressed after prior systemic therapy. According to
GlobalData analysts, Cabometyx's projected total annual sales could reach $3.3 billion by 2029, driven by its strong performance in its approved indications and label-expanding studies.
"As there is no standard of care for patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors whose disease has progressed after prior therapy, we are pleased to see that cabozantinib improved outcomes for two additional patient populations living with advanced, difficult-to-treat cancers," said Will Berg, M.D., Senior Vice President, Medical Affairs,
Exelixis. "We are grateful for the recommendation of the Data and Safety Monitoring Board to unblind the CABINET study early due to a dramatic improvement in efficacy and look forward to discussing these findings with the U.S. Food and Drug Administration."
In June 2023, researchers announced they'd found a "highly synergistic" combo featuring Krazati from
Mirati Therapeutics, Inc. (NASDAQ:MRTX) in pancreatic cancer models. The researchers found they could overcome drug resistance in combination with the
FDA-approved pan-ERBB inhibitor Afatinib.
Now
Mirati's successes will be passed along to
Bristol Myers Squibb, which entered a definitive merger agreement to be acquired for up to US$5.8 billion in value.
Another pharma giant making oncology moves is
Eli Lilly and Company (NYSE:LLY), which is set to acquire
POINT Biopharma Global Inc. (NASDAQ:PNT), for an aggregate of approximately US$1.4 billion.
Among the assets that
Lilly will be acquiring is PNT2004, which
POINT Biopharma, within its Phase 1 FRONTIER clinical trial, was evaluating five FAP-avid cancer indications, including pancreatic. As of the time of the
Lilly acquisition, the FRONTIER study was still underway, and as of the ASCO Annual Meeting in May 2023, still included pancreatic cancer as a segment.
"The combination of
POINT's team, infrastructure and capabilities with
Lilly's global resources and experience could significantly accelerate the discovery, development and global access to radiopharmaceuticals," said Joe McCann, Ph.D., CEO of
POINT. "I look forward to a future where patients all over the world can benefit from the new cancer treatment options made possible by the joining of our two companies today."
Article Source:
Article Source:
USA News Group
[email protected]
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains "forward-loking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
[email protected]
U.S. Phone: +1(954)345-0611
SOURCE USA News Group
